Corcept Therapeutics Incorporated CORT Stock
Corcept Therapeutics Incorporated Price Chart
Corcept Therapeutics Incorporated CORT Financial and Trading Overview
| Corcept Therapeutics Incorporated stock price | 79.85 USD |
| Previous Close | 79.91 USD |
| Open | 80.7 USD |
| Bid | 73.6 USD x 200 |
| Ask | 83.77 USD x 200 |
| Day's Range | 77.38 - 82 USD |
| 52 Week Range | 28.66 - 91 USD |
| Volume | 882.64K USD |
| Avg. Volume | 1.37M USD |
| Market Cap | 8.56B USD |
| Beta (5Y Monthly) | 0.501 |
| PE Ratio (TTM) | 227.74286 |
| EPS (TTM) | 0.35 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 88 USD |
CORT Valuation Measures
| Enterprise Value | 8.25B USD |
| Trailing P/E | 227.74286 |
| Forward P/E | 31.947897 |
| PEG Ratio (5 yr expected) | 0.81 |
| Price/Sales (ttm) | 11.126043 |
| Price/Book (mrq) | 13.410162 |
| Enterprise Value/Revenue | 10.727 |
| Enterprise Value/EBITDA | -1189.606 |
Trading Information
Corcept Therapeutics Incorporated Stock Price History
| Beta (5Y Monthly) | 0.501 |
| 52-Week Change | 7.57% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 91 USD |
| 52 Week Low | 28.66 USD |
| 50-Day Moving Average | 58.94 USD |
| 200-Day Moving Average | 59.96 USD |
CORT Share Statistics
| Avg. Volume (3 month) | 1.37M USD |
| Avg. Daily Volume (10-Days) | 1.05M USD |
| Shares Outstanding | 107.35M |
| Float | 89.9M |
| Short Ratio | 6.82 |
| % Held by Insiders | 11.54% |
| % Held by Institutions | 75.72% |
| Shares Short | 8.79M |
| Short % of Float | 10.56% |
| Short % of Shares Outstanding | 8.18% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 6.15% |
| Operating Margin (ttm) | -30.079% |
| Gross Margin | 98.25% |
| EBITDA Margin | -0.90% |
Management Effectiveness
| Return on Assets (ttm) | -0.61% |
| Return on Equity (ttm) | 7.16% |
Income Statement
| Revenue (ttm) | 769.1M USD |
| Revenue Per Share (ttm) | 7.4 USD |
| Quarterly Revenue Growth (yoy) | 4.90% |
| Gross Profit (ttm) | 755.64M USD |
| EBITDA | -6935000 USD |
| Net Income Avi to Common (ttm) | 46.68M USD |
| Diluted EPS (ttm) | 0.35 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 338.18M USD |
| Total Cash Per Share (mrq) | 3.15 USD |
| Total Debt (mrq) | 9.64M USD |
| Total Debt/Equity (mrq) | 1.51 USD |
| Current Ratio (mrq) | 2.856 |
| Book Value Per Share (mrq) | 5.944 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 120.45M USD |
| Levered Free Cash Flow (ttm) | 115.66M USD |
Profile of Corcept Therapeutics Incorporated
| Country | United States |
| State | CA |
| City | Redwood City |
| Address | 101 Redwood Shores Parkway |
| ZIP | 94065 |
| Phone | 650 327 3270 |
| Website | https://www.corcept.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 730 |
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Q&A For Corcept Therapeutics Incorporated Stock
What is a current CORT stock price?
Corcept Therapeutics Incorporated CORT stock price today per share is 79.85 USD.
How to purchase Corcept Therapeutics Incorporated stock?
You can buy CORT shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Corcept Therapeutics Incorporated?
The stock symbol or ticker of Corcept Therapeutics Incorporated is CORT.
Which industry does the Corcept Therapeutics Incorporated company belong to?
The Corcept Therapeutics Incorporated industry is Biotechnology.
How many shares does Corcept Therapeutics Incorporated have in circulation?
The max supply of Corcept Therapeutics Incorporated shares is 107.35M.
What is Corcept Therapeutics Incorporated Price to Earnings Ratio (PE Ratio)?
Corcept Therapeutics Incorporated PE Ratio is 228.14285000 now.
What was Corcept Therapeutics Incorporated earnings per share over the trailing 12 months (TTM)?
Corcept Therapeutics Incorporated EPS is 0.35 USD over the trailing 12 months.
Which sector does the Corcept Therapeutics Incorporated company belong to?
The Corcept Therapeutics Incorporated sector is Healthcare.
Corcept Therapeutics Incorporated CORT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3090.39 USD — |
-0.26
|
— — | 3063.94 USD — | 3108.39 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
4123.39 USD — |
-2.34
|
— — | 4089.8 USD — | 4163.55 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
|
US Tech Global BuyBack Achievers
DRBG
US
|
2924.65 USD — |
-0.47
|
— — | 2912.47 USD — | 2934.94 USD — | — - | — — |
|
US Tech Capital Market Composite
RCMP
US
|
146.53 USD — |
-0.75
|
— — | 144.14 USD — | 148.72 USD — | — - | — — |
|
US Tech US Smart Pharmaceuticals
NQSSPH
US
|
1926.14 USD — |
+1.34
|
— — | 1902.55 USD — | 1929.69 USD — | — - | — — |
|
US Tech US BuyBack Achievers Sel
DRBS
US
|
2340.09 USD — |
+0.42
|
— — | 2336.31 USD — | 2349.71 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
31560.2 USD — |
-2.21
|
— — | 31469.2 USD — | 31924.72 USD — | — - | — — |
- {{ link.label }} {{link}}